JP7688576B6 - 共生ウイルスに対するｔ細胞指向性抗がんワクチン - Google Patents

共生ウイルスに対するｔ細胞指向性抗がんワクチン Download PDF

Info

Publication number
JP7688576B6
JP7688576B6 JP2021530081A JP2021530081A JP7688576B6 JP 7688576 B6 JP7688576 B6 JP 7688576B6 JP 2021530081 A JP2021530081 A JP 2021530081A JP 2021530081 A JP2021530081 A JP 2021530081A JP 7688576 B6 JP7688576 B6 JP 7688576B6
Authority
JP
Japan
Prior art keywords
skin
hpv
mice
mmupv1
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021530081A
Other languages
English (en)
Japanese (ja)
Other versions
JP7688576B2 (ja
JP2022509221A5 (https=
JP2022509221A (ja
Inventor
デメーリ，シャドメア
Original Assignee
ザ ジェネラル ホスピタル コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ ジェネラル ホスピタル コーポレイション filed Critical ザ ジェネラル ホスピタル コーポレイション
Publication of JP2022509221A publication Critical patent/JP2022509221A/ja
Publication of JP2022509221A5 publication Critical patent/JP2022509221A5/ja
Priority to JP2024213945A priority Critical patent/JP2025060647A/ja
Publication of JP7688576B2 publication Critical patent/JP7688576B2/ja
Application granted granted Critical
Publication of JP7688576B6 publication Critical patent/JP7688576B6/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/05—Animals modified by non-integrating nucleic acids, e.g. antisense, RNAi, morpholino, episomal vector, for non-therapeutic purpose
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/876—Skin, melanoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20061—Methods of inactivation or attenuation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Environmental Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
JP2021530081A 2018-11-28 2019-11-26 共生ウイルスに対するｔ細胞指向性抗がんワクチン Active JP7688576B6 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024213945A JP2025060647A (ja) 2018-11-28 2024-12-06 共生ウイルスに対するｔ細胞指向性抗がんワクチン

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862772443P 2018-11-28 2018-11-28
US62/772,443 2018-11-28
US201962831691P 2019-04-09 2019-04-09
US62/831,691 2019-04-09
US201962909698P 2019-10-02 2019-10-02
US62/909,698 2019-10-02
PCT/US2019/063172 WO2020112720A1 (en) 2018-11-28 2019-11-26 T cell-directed anti-cancer vaccines against commensal viruses

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024213945A Division JP2025060647A (ja) 2018-11-28 2024-12-06 共生ウイルスに対するｔ細胞指向性抗がんワクチン

Publications (4)

Publication Number Publication Date
JP2022509221A JP2022509221A (ja) 2022-01-20
JP2022509221A5 JP2022509221A5 (https=) 2022-11-10
JP7688576B2 JP7688576B2 (ja) 2025-06-04
JP7688576B6 true JP7688576B6 (ja) 2025-07-04

Family

ID=70853016

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021530081A Active JP7688576B6 (ja) 2018-11-28 2019-11-26 共生ウイルスに対するｔ細胞指向性抗がんワクチン
JP2024213945A Pending JP2025060647A (ja) 2018-11-28 2024-12-06 共生ウイルスに対するｔ細胞指向性抗がんワクチン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024213945A Pending JP2025060647A (ja) 2018-11-28 2024-12-06 共生ウイルスに対するｔ細胞指向性抗がんワクチン

Country Status (5)

Country Link
US (1) US20220001004A1 (https=)
EP (1) EP3886886A4 (https=)
JP (2) JP7688576B6 (https=)
CN (1) CN113347987A (https=)
WO (1) WO2020112720A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7688576B6 (ja) * 2018-11-28 2025-07-04 ザ ジェネラル ホスピタル コーポレイション 共生ウイルスに対するｔ細胞指向性抗がんワクチン
WO2022159652A1 (en) * 2021-01-21 2022-07-28 The General Hospital Corporation T cell-directed anti-cancer vaccines against commensal viruses for treating mucosal carcinomas
US20230178197A1 (en) * 2021-12-03 2023-06-08 nference, inc. Techniques for predicting immunosuppression status
CN117982638B (zh) * 2024-02-04 2024-11-01 上海安奕康生物科技有限公司 免疫佐剂联合pd-1抗体药物在治疗胰腺癌中的应用
WO2025212374A1 (en) * 2024-04-02 2025-10-09 The General Hospital Corporation Methods for utilizing commensal polyomavirus for cancer therapy

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005505503A (ja) 2001-05-04 2005-02-24 コミッサリア　ア　レネルジ　アトミック Ｅ６及び／又はｅ７パピローマウイルスタンパク質に由来するペプチドの混合物並びにその使用
US20070014810A1 (en) 2003-12-31 2007-01-18 Denise Baker Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions
JP2010527630A (ja) 2007-05-31 2010-08-19 アカデミシュ ジーケンハウス ライデン エイチ．オー．ディー．エヌ． エルユーエムシー ワクチンで使用するための、子宮頸部悪性腫瘍に浸潤するｔ細胞によって標的とされるｈｐｖエピトープ

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT973546E (pt) * 1997-04-08 2004-06-30 Merck & Co Inc Formulacoes estabilizadas de virus de papiloma humano
EP1417353A4 (en) * 2001-07-20 2005-08-03 Univ Texas METHODS AND COMPOSITIONS ASSOCIATED WITH HPV ASSOCIATED PENCILS AND CANNULAR WELLS, INCLUDING CIN
US9149517B2 (en) * 2007-11-02 2015-10-06 The Johns Hopkins University Multitype HPV peptide compositions and methods for treatment or prevention of human papillomavirus infection
US9717783B2 (en) * 2010-02-09 2017-08-01 Stc.Unm Immunogenic HPV L2-containing VLPs and related compositions, constructs, and therapeutic methods
CN102229660B (zh) * 2011-05-25 2015-04-22 厦门大学 截短的人乳头瘤病毒33型l1蛋白
AU2016274655B2 (en) * 2015-06-10 2021-06-17 NeoTrail Therapeutics, Inc. HPV vaccines
JP7688576B6 (ja) * 2018-11-28 2025-07-04 ザ ジェネラル ホスピタル コーポレイション 共生ウイルスに対するｔ細胞指向性抗がんワクチン

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005505503A (ja) 2001-05-04 2005-02-24 コミッサリア　ア　レネルジ　アトミック Ｅ６及び／又はｅ７パピローマウイルスタンパク質に由来するペプチドの混合物並びにその使用
US20070014810A1 (en) 2003-12-31 2007-01-18 Denise Baker Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions
JP2010527630A (ja) 2007-05-31 2010-08-19 アカデミシュ ジーケンハウス ライデン エイチ．オー．ディー．エヌ． エルユーエムシー ワクチンで使用するための、子宮頸部悪性腫瘍に浸潤するｔ細胞によって標的とされるｈｐｖエピトープ

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
J. Virol.，2016年，Vol.90, No.14，pp.6314-6325
JAMA Dermatol.，2017年，Vol.153, No.6，pp.571-574
Vaccine，米国，2014年，Vol.32 , No.31，pp.3927-3935

Also Published As

Publication number Publication date
WO2020112720A9 (en) 2020-12-24
JP7688576B2 (ja) 2025-06-04
EP3886886A4 (en) 2022-08-24
EP3886886A1 (en) 2021-10-06
CN113347987A (zh) 2021-09-03
WO2020112720A1 (en) 2020-06-04
JP2022509221A (ja) 2022-01-20
US20220001004A1 (en) 2022-01-06
JP2025060647A (ja) 2025-04-10

Similar Documents

Publication Publication Date Title
JP7688576B2 (ja) 共生ウイルスに対するｔ細胞指向性抗がんワクチン
Lin et al. Intratumoral delivery of a PD-1–blocking scFv encoded in oncolytic HSV-1 promotes antitumor immunity and synergizes with TIGIT blockade
Che et al. Induction of systemic immune responses and reversion of immunosuppression in the tumor microenvironment by a therapeutic vaccine for cervical cancer
Vinzón et al. Protective vaccination against papillomavirus-induced skin tumors under immunocompetent and immunosuppressive conditions: a preclinical study using a natural outbred animal model
Routhu et al. A modified vaccinia Ankara vaccine expressing spike and nucleocapsid protects rhesus macaques against SARS-CoV-2 Delta infection
JP6936153B2 (ja) Ｍｖａ又はｍｖａδｅ３ｌの固形腫瘍免疫療法剤としての使用
AU2016259020B2 (en) Dendritic cell immunotherapy
Smola Human papillomaviruses and skin cancer
JP2018524335A (ja) Ｈｉｖ予備免疫化および免疫療法
US20060153808A1 (en) Cancer immunotherapy incorporating p53
WO2022228538A1 (zh) 一种表达免疫调节因子的car载体及其应用
US20220273589A1 (en) Diagnosis and Treatment of Vitiligo
Smola Human Papilloma Viruses and Skin Cancer
US20150044667A1 (en) Human papillomavirus 16 (hpv16) - related epilepsy
Johnson et al. Compromised T cell immunity links increased cutaneous papillomavirus activity to squamous cell carcinoma risk
Prins et al. HPV16 E6 and E7 expressing cancer cells suppress the antitumor immune response by upregulating KLF2-mediated IL-23 expression in macrophages
TW201725050A (zh) 抗癌疫苗組合
JP2002532434A (ja) パピローマウイルス感染の治療方法
Ramdass et al. Cancer-initiating cells as target for prevention of recurring disease etiology: role of these malignant putative progenitor cells in relapse or metastasis of human cervical carcinoma
US20200375965A1 (en) Targeting Lipid Metabolism and Free Fatty Acid (FFA) Oxidation to Treat Diseases Mediated by Resident Memory T Cells (TRM)
US20240100141A1 (en) T cell-directed anti-cancer vaccines against commensal viruses for treating mucosal carcinomas
Hirschhorn-Cymerman et al. T cell immunotherapies trigger neutrophil activation to eliminate tumor antigen escape variants
Vallcorba Immuno-virotherapy for glioblastoma: Characterization of Delta-24-ACT in combination with different immunomodulators as therapeutic approach
US20250064919A1 (en) A SARS-COV-2 Human Parainfluenza Virus Type 3-Vectored Vaccine
Notaro Lentiviral vector-based tumor vaccines to expand and activate tumor-reactive T cells

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221101

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221101

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20231031

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231107

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240207

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240408

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240507

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240806

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241206

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250415

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250416

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250430

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250523

R150 Certificate of patent or registration of utility model

Ref document number: 7688576

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150